To the Editor:
==============

Abnormalities in coagulation with increased venous thromboembolism (VTE) are now reported in critically ill coronavirus disease 2019 (COVID-19) patients ([@R1], [@R2]). Potential explanations of the activation of coagulation in COVID-19 ICU patients are the vessel wall inflammation and the cytokine storm that activate the coagulation pathways associated perhaps with decreased concentrations of physiologic anticoagulant proteins ([@R2]--[@R5]). This imbalance favors thrombus formation which is associated with poor outcome. COVID-19 ICU patients also have more thrombotic events than patients suffering from non-COVID-19 pneumonia ([@R2]). It seemed a crucial issue to ensure optimized thromboprophylaxis in all COVID-19 patients and, in particular, in ICU patients.

Although several expert opinion and scientific societies reported VTE guidelines for critically ill COVID-19 patients with significantly raised [d]{.smallcaps}-dimer concentrations, the optimal dose of low-molecular-weight heparin (LMWH) remains unclear ([@R4]--[@R8]). Furthermore, LMWH has also anti-inflammatory properties that might be beneficial in COVID-19 patients ([@R4], [@R5], [@R7]). Here, we report our adapted thromboprophylaxis practice of LMWH administration in COVID-19 ICU patients with a body mass index (BMI) adjusted dose of enoxaparin (40 mg for BMI \< 30, 60 mg for BMI \> 30 and \< 40, and 80 mg for BMI \> 40 kg/m^2^) in patients with a creatinine clearance greater than or equal to 30 mL/min and with platelets count greater than or equal to 100,000/mm^3^. This made it possible to obtain homogeneous doses of at least 1 mg/kg of body weight of enoxaparin in agreement with some guidelines ([@R2], [@R5], [@R9]). Due to the higher frequency of acute renal failure in ICU patients ([@R2]), we measured especially the trough anti-Xa activity. In some patients, we also reported the anti-Xa activity peaks.

We performed 106 measurements in 19 COVID-19 ICU patients during the month of April 2020 in the ICU from the CHU-Charleroi Marie Curie after approval by the Ethical Committee. The median age was 58 years, all except five were mechanically ventilated for acute respiratory distress syndrome due to severe acute respiratory syndrome coronavirus 2 infection. ICU mortality was 26%. Demographic and biological data are reported in **Table [1](#T1){ref-type="table"}**. Trough anti-Xa for all patients is reported in **Figure [1](#F1){ref-type="fig"}**.
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![Trough anti-Xa activity in ICU patients with coronavirus disease 2019. *Box plot* for the through anti-Xa activity. The *hatched line* represents the limit of the trough anti-Xa activity. IU = international units.](cc9-2-e0177-g002){#F1}

Despite enoxaparin 60 mg once daily, only two measurements were at the upper end of the prophylactic range (\< 0.3 anti-Xa international units \[IU\]/mL). In eight patients, anti-Xa activity peaks were performed and increased significantly after administration (0.059 ± 0.085 vs 0.277 ± 0.151 anti-Xa IU/mL; *p* = 0.009; paired *t* test) but all measurements were under the optimal prophylactic ranges of 0.65 ± 0.17 anti-Xa IU/mL. Three of the 19 patients (16%) developed VTE between 6 and 8 days after the adaptation of the protocol of thromboprophylaxis.

Our results showed that despite higher prophylactic LMWH administration due to BMI in COVID-19 ICU patients as recommended, trough anti-Xa activity remains in the majority low and without risk of bleeding. Anti-Xa activity was well below peak serum levels in our cohort of critically ill COVID-19 patients. Despite treatment, three patients developed VTE during this adapted protocol.

Our evaluation suggests that current thromboprophylaxis guidelines are ineffective in COVID-19 ICU patients. Thrombotic complications were frequently reported and associated with higher mortality in critically ill COVID-19 patients. The medical community needs to rapidly determine optimal thromboprophylaxis for COVID-19 patients, especially in high-risk critically ill patients.
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